v3.25.2
OUT-LICENSE AGREEMENTS (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 6 Months Ended
Apr. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Mar. 31, 2021
LianBio        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Special cash dividends paid   $ 0.7 $ 0.7  
Special cash dividend (usd per share)   $ 4.80    
LianBio | License agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Upfront payment       $ 15.0
Additional cash payment       10.0
Amortized cost       1.2
Revenue recognized $ 2.5   86.1  
Proceeds from warrant cancellation payment   $ 0.4    
Upfront payment received     15.0  
LianBio | License agreement | Milestone Determined by the Company        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Milestone payments to be achieved       $ 10.0
LianBio | License agreement | Development and Regulatory Milestone        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Milestone payments to be achieved     67.5  
LianBio | License agreement | Upon Execution of the Novation Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Milestone payments to be achieved     2.5  
LianBio | License agreement | Upon Execution of Warrant Termination Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Milestone payments to be achieved     0.4  
Grandpharma | License agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Maximum milestone payments     100.0  
Grandpharma | License agreement | Development and Regulatory Milestone        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Maximum milestone payments     $ 20.0